Multimodal Imaging Techniques to Evaluate the Anticancer Effect of Cold Atmospheric Pressure Plasma.
kINPen™
malignant melanoma
plasma medicine
reactive oxygen and nitrogen species
skin cancer
squamous cell carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 May 2021
19 May 2021
Historique:
received:
23
03
2021
revised:
14
05
2021
accepted:
16
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Skin cancer is the most frequent cancer worldwide and is divided into non-melanoma skin cancer, including basal cell carcinoma, as well as squamous cell carcinoma (SCC) and malignant melanoma (MM). This study evaluates the effects of cold atmospheric pressure plasma (CAP) on SCC and MM in vivo, employing a comprehensive approach using multimodal imaging techniques. Longitudinal MR and PET/CT imaging were performed to determine the anatomic and metabolic tumour volume over three-weeks in vivo. Additionally, the formation of reactive species after CAP treatment was assessed by non-invasive chemiluminescence imaging of L-012. Histological analysis and immunohistochemical staining for Ki-67, ApopTag As the main result, multimodal in vivo imaging revealed a substantial reduction in tumour growth and an increase in reactive species after CAP treatment, in comparison to untreated tumours. In contrast, neither the markers for apoptosis, nor the metabolic activity of both tumour entities was affected by CAP. These findings propose CAP as a potential adjuvant therapy option to established standard therapies of skin cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Skin cancer is the most frequent cancer worldwide and is divided into non-melanoma skin cancer, including basal cell carcinoma, as well as squamous cell carcinoma (SCC) and malignant melanoma (MM).
METHODS
METHODS
This study evaluates the effects of cold atmospheric pressure plasma (CAP) on SCC and MM in vivo, employing a comprehensive approach using multimodal imaging techniques. Longitudinal MR and PET/CT imaging were performed to determine the anatomic and metabolic tumour volume over three-weeks in vivo. Additionally, the formation of reactive species after CAP treatment was assessed by non-invasive chemiluminescence imaging of L-012. Histological analysis and immunohistochemical staining for Ki-67, ApopTag
RESULTS
RESULTS
As the main result, multimodal in vivo imaging revealed a substantial reduction in tumour growth and an increase in reactive species after CAP treatment, in comparison to untreated tumours. In contrast, neither the markers for apoptosis, nor the metabolic activity of both tumour entities was affected by CAP.
CONCLUSIONS
CONCLUSIONS
These findings propose CAP as a potential adjuvant therapy option to established standard therapies of skin cancer.
Identifiants
pubmed: 34069689
pii: cancers13102483
doi: 10.3390/cancers13102483
pmc: PMC8161248
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Social Fund
ID : ESF/14-BM-A55-0003/18
Organisme : European Social Fund
ID : ESF/14-BM-A55-0001/18
Organisme : European Social Fund
ID : ESF/14-BM-A55-0006/18
Références
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3687-3692
pubmed: 32029590
Redox Biol. 2021 Jan;38:101809
pubmed: 33271456
Oncotarget. 2017 Sep 16;8(56):95606-95619
pubmed: 29221153
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
NMR Biomed. 2017 Mar;30(3):
pubmed: 26773848
Oncotarget. 2017 Jul 15;8(41):69756-69767
pubmed: 29050239
Cochrane Database Syst Rev. 2019 Jul 01;7:CD012806
pubmed: 31260100
Free Radic Biol Med. 2020 Dec;161:32-49
pubmed: 33011275
PLoS One. 2014 Jul 28;9(7):e103349
pubmed: 25068311
Cancer Imaging. 2018 Jan 18;18(1):2
pubmed: 29347968
Plasma Process Polym. 2015 Dec;12(12):1400-1409
pubmed: 29104522
Anal Biochem. 1999 Jun 15;271(1):53-8
pubmed: 10361004
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Sci Rep. 2012;2:636
pubmed: 22957140
Free Radic Biol Med. 2013 Dec;65:1310-1314
pubmed: 24080119
Int J Mol Med. 2014 Oct;34(4):941-6
pubmed: 25050490
Luminescence. 2014 Mar;29(2):118-21
pubmed: 23630098
Cancers (Basel). 2020 Nov 30;12(12):
pubmed: 33265951
Free Radic Biol Med. 2009 Sep 15;47(6):760-6
pubmed: 19539751
Sci Rep. 2018 Aug 24;8(1):12734
pubmed: 30143716
Mol Biol Cell. 2014 May;25(9):1523-31
pubmed: 24574456
Sci Rep. 2020 Nov 13;10(1):19814
pubmed: 33188220
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56
pubmed: 12098606
Semin Oncol Nurs. 2013 Aug;29(3):160-9
pubmed: 23958214
Cells. 2019 Aug 13;8(8):
pubmed: 31412684
Biomedicine (Taipei). 2015 Nov;5(4):19
pubmed: 26613930
Br J Cancer. 2011 Oct 25;105(9):1295-301
pubmed: 21979421
Adv Sci (Weinh). 2020 Mar 30;7(10):1903438
pubmed: 32440479
J Am Acad Dermatol. 2016 Jul;75(1):186-96
pubmed: 26992283
Prim Care. 2015 Dec;42(4):645-59
pubmed: 26612377
Mol Imaging Biol. 2020 Jun;22(3):504-514
pubmed: 31482411
Int J Cancer. 2012 May 1;130(9):2185-94
pubmed: 21702038
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910